(Q36500200)

14 August 2017

1 reference

title

The effects of chronic phosphodiesterase-5 inhibitor use on different organ systems (English)

1 reference

14 August 2017

Schwarz ER

1

1 reference

14 August 2017

Kapur V

2

1 reference

14 August 2017

Rodriguez J

3

1 reference

14 August 2017

Rastogi S

4

1 reference

14 August 2017

Rosanio S

5

1 reference

14 August 2017

language of work or name

1 reference

8 June 2006

1 reference

International Journal of Impotence Research

14 August 2017

published in

1 reference

14 August 2017

volume

19

1 reference

14 August 2017

issue

2

1 reference

14 August 2017

page(s)

139-148

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.ijir.3901491

14 August 2017

exact match

0 references

cites work

Therapeutic potential of phosphodiesterase 5 inhibition for cardiovascular disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901491

Cardiac phosphodiesterase 5 (cGMP-specific) modulates beta-adrenergic signaling in vivo and is down-regulated in heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901491

Phosphodiesterase type 5 as a pharmacologic target in erectile dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901491

Clinical and haemodynamic effects of sildenafil in pulmonary hypertension: acute and mid-term effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901491

Effects of sildenafil citrate on human hemodynamics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901491

Cyclic nucleotide phosphodiesterase type 5 activity limits blood flow to hypoperfused myocardium during exercise

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901491

Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901491

Impaired muscarinic endothelium-dependent relaxation and cyclic guanosine 5'-monophosphate formation in atherosclerotic human coronary artery and rabbit aorta

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901491

Low basal and stimulated release of nitric oxide in atherosclerotic epicardial coronary arteries

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901491

Impotence and aging: clinical and hormonal factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901491

Erectile dysfunction is a marker for cardiovascular disease: results of the minority health institute expert advisory panel

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901491

Role of nitric oxide in the physiology of erection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901491

Identification of the cytochrome P450 enzymes involved in the N-demethylation of sildenafil

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901491

The effects of steady-state erythromycin and azithromycin on the pharmacokinetics of sildenafil in healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901491

The effects of cimetidine and antacid on the pharmacokinetic profile of sildenafil citrate in healthy male volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901491

Minimal time to successful intercourse after sildenafil citrate: results of a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901491

Effects of tadalafil on erectile dysfunction in men with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901491

Sildenafil in the treatment of erectile dysfunction in men with diabetes: demand, efficacy and patient satisfaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901491

Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901491

Efficacy and safety of sildenafil citrate in the treatment of erectile dysfunction in patients with ischemic heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901491

The effects of phosphodiesterase-5 inhibition with sildenafil on pulmonary hemodynamics and diffusion capacity, exercise ventilatory efficiency, and oxygen uptake kinetics in chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901491

Effect of sildenafil on the acute pulmonary vasodilator response to inhaled nitric oxide in adults with primary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901491

Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901491

Tadalafil in primary pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901491

Sildenafil for long-term treatment of nonoperable chronic thromboembolic pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901491

Treatment of pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901491

Long-Term Treatment With Oral Sildenafil Is Safe and Improves Functional Capacity and Hemodynamics in Patients With Pulmonary Arterial Hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901491

Sildenafil citrate does not affect cardiac contractility in human or dog heart

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901491

Sildenafil inhibits beta-adrenergic-stimulated cardiac contractility in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901491

Effect of sildenafil on blood pressure and arterial wave reflection in treated hypertensive men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901491

Cardiovascular parameter changes in patients with erectile dysfunction using pde-5 inhibitors: a study with sildenafil and vardenafil

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901491

Sildenafil effects on exercise, neurohormonal activation, and erectile dysfunction in congestive heart failure: a double-blind, placebo-controlled, randomized study followed by a prospective treatment for erectile dysfunction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901491

Use of sildenafil for safe improvement of erectile function and quality of life in men with New York Heart Association classes II and III congestive heart failure: a prospective, placebo-controlled, double-blind crossover trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901491

Potential role of type 5 phosphodiesterase inhibition in the treatment of congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901491

The effect of Sildenafil on human platelet secretory function is controlled by a complex interplay between phosphodiesterases 2, 3 and 5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901491

ACC/AHA expert consensus document. Use of sildenafil (Viagra) in patients with cardiovascular disease. American College of Cardiology/American Heart Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901491

Inhibitory effect of sildenafil on rat duodenal contractility in vitro: putative cGMP involvement.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901491

Effect of sildenafil, a phosphodiesterase-5 inhibitor, on oesophageal peristalsis and lower oesophageal sphincter function in cats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901491

Influence of sildenafil on gastric sensorimotor function in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901491

Phosphodiesterase inhibitors cause relaxation of the internal anal sphincter in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901491

Why do patients with heart failure suffer from erectile dysfunction? A critical review and suggestions on how to approach this problem

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901491

Chronic administration of phosphodiesterase 5 inhibitor improves erectile and endothelial function in a rat model of diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901491

Sildenafil prevents endothelial dysfunction induced by ischemia and reperfusion via opening of adenosine triphosphate-sensitive potassium channels: a human in vivo study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901491

Chronic treatment with tadalafil improves endothelial function in men with increased cardiovascular risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901491

Sildenafil does not improve nitric oxide-mediated endothelium-dependent vascular responses in smokers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901491

Type 5 phosphodiesterase inhibition by sildenafil abrogates acute smoking-induced endothelial dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901491

Ocular safety in patients using sildenafil citrate therapy for erectile dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901491

Anterior ischemic optic neuropathy associated with viagra

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901491

Pupil-sparing third nerve palsy associated with sildenafil citrate (Viagra).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901491

Sildenafil citrate use and the incidence of nonarteritic anterior ischemic optic neuropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901491

Expression of cGMP-binding cGMP-specific phosphodiesterase (PDE5) in mouse tissues and cell lines using an antibody against the enzyme amino-terminal domain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901491

The role of cGMP hydrolysing phosphodiesterases 1 and 5 in cerebral artery dilatation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901491

Effect of sildenafil (Viagra®) on cerebral blood flow velocity: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901491

Chronic sildenafil treatment inhibits monocrotaline-induced pulmonary hypertension in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901491

Phosphodiesterase-5 inhibition with sildenafil attenuates cardiomyocyte apoptosis and left ventricular dysfunction in a chronic model of doxorubicin cardiotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901491

Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901491

Effects of long-term vardenafil treatment on the development of fibrotic plaques in a rat model of Peyronie's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901491

Long-term treatment with oral sildenafil in addition to continuous IV epoprostenol in patients with pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901491

One-year follow-up of the effects of sildenafil on pulmonary arterial hypertension and veno-occlusive disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901491

Chronic outpatient sildenafil therapy for pulmonary hypertension in a child after cardiac surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901491

Acute and chronic effects of sildenafil in patients with pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901491

Cardiovascular effects of tadalafil

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901491

Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901491

7 January 2021

Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901491

7 January 2021

Large coronary arteries in humans are responsive to changing blood flow: an endothelium-dependent mechanism that fails in patients with atherosclerosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901491

7 January 2021

The prevalence of hypertension, hyperlipidemia, diabetes mellitus and depression in men with erectile dysfunction

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901491

7 January 2021

Cigarette smoking and other vascular risk factors in vasculogenic impotence

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901491

7 January 2021

Modifiable risk factors and erectile dysfunction: can lifestyle changes modify risk?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901491

7 January 2021

Physiology of penile erection

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901491

7 January 2021

Effects of sildenafil on human penile blood vessels

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901491

7 January 2021

Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901491

7 January 2021

Nitric oxide and the lung

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901491

7 January 2021

Hemodynamic effects of sildenafil in men with severe coronary artery disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901491

7 January 2021

Acute type 5 phosphodiesterase inhibition with sildenafil enhances flow-mediated vasodilation in patients with chronic heart failure

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901491

7 January 2021

Identifiers

DOI

10.1038/SJ.IJIR.3901491

1 reference

14 August 2017

1 reference